|Bid||0.00 x 3200|
|Ask||0.00 x 800|
|Day's Range||83.93 - 84.89|
|52 Week Range||77.82 - 91.79|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||0.14%|
In an effort to stave off Amazon, CVS will roll-out nationwide delivery of prescription medication. Yahoo Finance's Seana Smith, Ethan Wolff-Mann, David Pogue and Rick Newman discuss.
The US added 223,000 jobs in May while the unemployment rate dropped to 3.8%. Yahoo Finance's Seana Smith, Pras Subramanian and Andy Serwer discuss the report with Shawn Snyder, Head of Investment Strategy at Citigroup Global.
Consumer prices in the United States grew 2.8% year over year in May 2018, above market expectations of 2.7%. It also marked the highest inflation rate since February 2012. Higher cost of gasoline and shelter led to the estimate beat.
The sector with some of the hottest stocks in the past decade, tech segments remain the fastest growing industries today. The “FAANG” contingent of Facebook Inc. (NASDAQ: FB), Amazon.com, Inc. (NASDAQ: AMZN), Apple Inc. (NASDAQ: AAPL), Netflix, Inc. (NASDAQ: NFLX) and Google-parent Alphabet Inc. (NASDAQ: GOOG) (NASDAQ: GOOGL) have resumed their upward climb after stumbling earlier in the year. Semiconductor plays like NVIDIA Corporation (NASDAQ: NVDA) and Advanced Micro Devices, Inc. (NASDAQ: AMD) have also been huge sources of strength.
High and growing health-care costs are a problem for everyone — but especially so for state and local governments. Related: Doctor’s offices are a hot investment — what does that mean for profit vs. patient care?FitchU.S. state and local governments spent 30.7% of their budgets on health care and social services in 2015, an increase from 27.6% in 2005.
Johnson & Johnson (JNJ.N) shareholders have endured a painful year amid worries about prospects for its many businesses, but investors capitalizing on the stock's relatively cheap valuation may be set to apply a Band-Aid to the declines. Shares of J&J, the largest U.S. healthcare company by market value, had slumped 11.2 percent this year as of Friday's close, although recent gains may indicate the start of a rebound. The stock's year-to-date decline compares to more than 2 percent gains for both the S&P 500 healthcare sector (.SPXHC) and the blue chip Dow Jones Industrial Average (.DJI), of which J&J is a member.
Investors looking for a sector level summer rental in the financial markets may want to consider healthcare ETFs, such as the Health Care Select Sector SPDR (XLV). XLV allocates about two-thirds of its combined weight to pharmaceuticals and biotechnology stocks. There are other catalysts to consider, including that the U.S. economy is moving into the late-cycle phase, overall growth may slow and signs of an economic slowdown could pop up.
Pharmaceutical ETFs are securities that are publicly traded on the stock market and designed for investors wanting to diversify their investments in the pharmaceutical sector.
Biotech stocks—with their binary outcomes and potential FDA approvals or denials—should whip around, pending various outcomes. It doesn’t help that President Trump (seemingly at random) decides periodically that we all pay too much for drugs. For biotech stocks to work on the long side investors’ risk appetite would have to take off or a major approval could drive the stocks up.
June can be a rough month for U.S. stocks. The sixth month of the year is the fourth-worst for both the S&P 500 and the Dow Jones Industrial Average. Not surprisingly, that the theme of broader market ...